ISTA Pharmaceuticals explained

ISTA Pharmaceuticals, Inc.
Type:	Subsidiary
Foundation:	1992
Location:	Irvine, California
Key People:	Vicente Anido Jr., Ph.D. Glenn E. Davis Marvin J. Garrett Kathleen McGinley
Industry:	Pharmaceuticals
Products:	Bromday, Bepreve, Xibrom, Istalol, Vitrase

ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.^[1] ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012.^[2] Under the deal, Bausch & Lomb have agreed to pay $9.10 per share for ISTA, bringing the total value of the acquisition to $500 million.^[3] In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.^[4]

Products

• Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction^[5]
• Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis^[6]
• Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
• Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma^[7]
• Vitrase (hyaluronidase injection) Ovine, 200 USP units/mL for use as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents^[8]

Litigation

On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.^[9]

External links

• ISTA homepage

Notes and References

1. Web site: ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance . Finance.yahoo.com . October 28, 2009.
2. Web site: Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million. Peter. Lattman. DealBook. 26 March 2012 . January 29, 2019.
3. Web site: Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million. Lattman. Peter. 2012-03-26. DealBook. en. 2019-10-21.
4. Web site: Valeant Sticks to Torrid Pace of Deal-Making. Mark. Scott. DealBook. 4 September 2012 . January 29, 2019.
5. Web site: BROMDAY™ | Products . March 21, 2011 . dead . https://web.archive.org/web/20110713070403/http://www.istavision.com/products/bromday.html . 2011-07-13 .
6. Web site: Relief from Allergic Conjunctivitis - BEPREVE : Bausch + Lomb. www.Bausch.com. January 29, 2019.
7. Web site: Bausch Consumer > en > ecp > our-products. www.Bausch.com. January 29, 2019.
8. Web site: Bausch Consumer > en > ecp > our-products. www.Bausch.com. January 29, 2019.
9. Web site: ISTA Pharmaceuticals Inc. Pleads Guilty to Federal Felony Charges; Will Pay $33.5 Million to Resolve Criminal Liability and False Claims Act Allegations. May 24, 2013. www.Justice.gov. January 29, 2019.